Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Inclusion Criteria: * Willingness to provide written informed consent for the study. * Willingness to undergo a pretreatment and on-treatment tumor biopsy to obtain tumor tissue. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Part 1: Subjects with histologically or cytologically confirmed advanced or metastatic solid tumors that have failed prior standard therapy (disease progression; subject refusal or intolerance is also allowable). * Part 2: \*Note: Subjects must have failed available therapies that are known to confer clinical benefit as indicated below, unless they are ineligible, intolerant, or refused standard treatment. * Subjects with histologically or cytologically confirmed NSCLC: * Metastatic (Stage IV) or recurrent NSCLC (according to American Joint Committee on Cancer 7th edition guidelines) who have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment. * Prior systemic regimens must include previously approved therapies, including a platinum-containing chemotherapy regimen; a tyrosine kinase inhibitor for tumors with driver mutations; and checkpoint inhibitors where approved. * Must have disease progression on a prior PD-1-pathway targeted agent. * Subjects with recurrent (unresectable) or metastatic CRC: * Have histologically confirmed microsatellite stable (MSS) CRC. * Stage IV MSS …